top of page
Executive Spotlights

GenKOre has inked a research collab worth up to $350M to develop new in vivo gene editing therapies

Seoul, South Korea, January 25, 2023 (PRNewswire) -- GenKOre, Inc., a Korea-based biotech company with hypercompact CRISPR-Cas tools, announced that it has entered into a strategic research collaboration with a US-based biopharma company for the development of in vivo gene editing therapies. This collaboration will utilize GenKOre's proprietary CRISPR-Cas platform, TaRGET (Tiny nuclease, augment RNA-based Genome Editing Technology).

Read full article here.

Recent Posts

See All


Life Science Headlines
bottom of page